Chinese biopharma firm IMPACT closes $55m Series D+ round to advance cancer drugs
The Series D+ round was led by GTJA Investment Group and Beijing-based state capital investor Kingray Capital.
Leiwen Chen Junshi Biosciences National Medical Products Administration Yangzhou Guojin Group Investment Group Drug Administration
Source: dealstreetasia.com